609-537-6363

609-537-6363
MAKE AN APPOINTMENT
  • ADVANCED
    TREATMENTS

Cancer Research at Capital Health

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and clinical research staff carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study.

Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure “Taking Part in Cancer Treatment Research Studies” to help you understand the details of clinical trials.

To learn more about our ongoing trials for cancer treatment and prevention, please complete the form below and one of our team members will contact you directly! 


Active Clinical Trials Currently Offered:

Brain Studies

3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors

  • Study Information: NCT03561207 (https://clinicaltrials.gov/ct2/show/NCT03561207)
  • Sponsor: KIYATEC, Inc.
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact:  Office of Clinical Research at 609-394-4130

 

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Molecular and biochemical characterization of malignant and metastatic brain tumors

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Genomically-guided treatment trial in brain metastasis

  • Study Information: NCT03994796, NCTN# A071701 (https://clinicaltrials.gov/ct2/show/NCT03994796)
  • Sponsor: Alliance for Clinical Trials
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Dr. Neel Gandhi, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

 

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma With Elevated Mutational Burden

  • Study Information: NCT04145115; NCTN # A071702 (https://clinicaltrials.gov/ct2/show/NCT04145115)
  • Sponsor: Alliance in Clinical Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Testing the Use of the Immunotherapy Drugs, Ipilimumab and Nivolumab, Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  • Study Information: NCT04396860; NCTN # NRG BN007 (https://clinicaltrials.gov/ct2/show/NCT04396860)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Neel Gandhi, MD, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

 

Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Liver and Pancreas Studies

Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT

  • Study Information: NCT03899649 (https://clinicaltrials.gov/ct2/show/NCT03899649)
  • Sponsor: Angiodynamics, Inc.
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Circulating Biomarkers and Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Gynecological Studies

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

  • Study Information: NCT04251052, NCTN# CC008 (https://clinicaltrials.gov/ct2/show/NCT04251052)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Gynecologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4130

Lung Studies

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer” with Protocol number M14-239

  • Principal Investigator: Dr. Scott Kindsfather, Hematologic and Oncologic Diseases
  • Sub-Investigator: Dr. Africa Wallace, Thoracic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC

  • Study Information: NCT0421462, NCTN #S1914 (https://clinicaltrials.gov/ct2/show/NCT04214262)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer

  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

  • Study Information: NCT03811002; NCTN #NRG-LU005 (https://clinicaltrials.gov/ct2/show/NCT03811002)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Gastro-Intestinal Studies

A randomized trial of the altering intake, managing symptoms interventions for bowel dysfunction in rectal cancer survivors compared to a healthy living education control: A feasibility and preliminary efficacy study (AIMS-RC) S1820

Bespoke Study of ctDNA Guided Therapy in Colorectal Cancer

  • Study Information: NCT04264702 (https://clinicaltrials.gov/ct2/show/NCT04264702)
  • Sponsor: NATERA
  • Principal investigator: Dr. Ashlee Godshalk-Ruggles, Colo-Rectal Surgery
  • Sub-Investigator: Dr. Hongyan Liang, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

Other Studies

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

  • Study Information: NCT02465060, NCTN# EAY131 (https://clinicaltrials.gov/ct2/show/NCT02465060)
  • Sponsor: National Cancer Institute (NCI)
  • Principal Investigator: David Schaebler, MD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Cancer Tissue Biorepository

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130

Urogenital Studies

Diagnostic Markers in Patients with Bladder Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

Stereotactic Body Radiation Therapy or Intesity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

  • Study Information: NCT03367702; NCTN #NRG-GU005 (https://clinicaltrials.gov/ct2/show/NCT03367702)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Timothy Chen, MD, Radiation Oncologist, Medical Director, Stereotactic Radiosurgery
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

Brain Studies

OBSERVATION OR RADIATION THERAPY IN TREATING PATIENTS WITH NEWLY DIAGNOSED GRADE II MENINGIOMA THAT HAS BEEN COMPLETELY REMOVED BY SURGERY

  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF MALIGNANT AND METASTATIC BRAIN TUMORS

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASIS

  • Study Information: NCT03994796, NCTN# A071701 (https://clinicaltrials.gov/ct2/show/NCT03994796)
  • Sponsor: Alliance for Clinical Trials
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Dr. Neel Gandhi, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130
  •  

A STUDY TESTING THE EFFECT OF IMMUNOTHERAPY (IPILIMUMAB AND NIVOLUMAB) IN PATIENTS WITH RECURRENT GLIOBLASTOMA WITH ELEVATED MUTATIONAL BURDEN

  • Study Information: NCT04145115; NCTN # A071702 (https://clinicaltrials.gov/ct2/show/NCT04145115)
  • Sponsor: Alliance in Clinical Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

ASSESSING QUALITY OF LIFE IN ADULT NEURO-ONCOLOGY PATIENTS AFTER CYBERKNIFE OR WBRT (WHOLE BRAIN RADIATION THERAPY), A PROSPECTIVE REGISTRY

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

THE USE OF THE KETOGENIC DIET AS AN ADJUVANT TO TREATMENT OF GLIOBLASTOME MULTIFORME

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

NRG-BN012: A RANDOMIZED PHASE III TRIAL OF PRE-OPERATIVE COMPARED TO POST-OPERATIVE STEREOTACTIC RADIOSURGERY IN PATIENTS WITH RESECTABLE BRAIN METASTASES
Date added: January, 2023

Liver and Pancreas Studies

CIRCULATING BIOMARKERS AND CANCER

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Date added: May, 2023

  • Study Information: NCT04998552
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Shirnett Williamson, MD, Medical Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

Gynecological Studies

A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS

  • Study Information: NCT04251052, NCTN# CC008 (https://clinicaltrials.gov/ct2/show/NCT04251052)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Gynecologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4130

Lung Studies

PHASE 2, OPEN-LABEL SAFETY AND EFFICACY STUDY OF TELISOTUZUMAB VEDOTIN (ABBV-399) IN SUBJECTS WITH PREVIOUSLY TREATED C-MET+ NON-SMALL CELL LUNG CANCER” WITH PROTOCOL NUMBER M14-239

  • Principal Investigator: Dr. Scott Kindsfather, Hematologic and Oncologic Diseases
  • Sub-Investigator: Dr. Africa Wallace, Thoracic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

A RANDOMIZED PHASE III TRIAL OF INDUCTION/CONSOLIDATION ATEZOLIZUMAB + SBRT VERSUS SBRT ALONE IN HIGH RISK, EARLY STAGE NSCLC

  • Study Information: NCT0421462, NCTN #S1914 (https://clinicaltrials.gov/ct2/show/NCT04214262)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

SWOG S1827 (MAVERICK) TESTING WHETHER THE USE OF BRAIN SCANS ALONE INSTEAD OF BRAIN SCANS PLUS PREVENTIVE BRAIN RADIATION AFFECTS LIFESPAN IN PATIENTS WITH SMALL CELL LUNG CANCER

  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

TESTING THE ADDITION OF RADIATION THERAPY TO THE USUAL IMMUNE THERAPY TREATMENT (ATEZOLIZUMAB) FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER, THE RAPTOR TRIAL

  • Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Gastro-Intestinal Studies

BESPOKE STUDY OF CTDNA GUIDED THERAPY IN COLORECTAL CANCER

  • Study Information: NCT04264702 (https://clinicaltrials.gov/ct2/show/NCT04264702)
  • Sponsor: NATERA
  • Principal investigator: Dr. Ashlee Godshalk-Ruggles, Colo-Rectal Surgery
  • Sub-Investigator: Dr. Hongyan Liang, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130
  • NOTE: Active, but no longer enrolling new patients.

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Other Studies

CANCER TISSUE BIOREPOSITORY

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130

Evaluate Tests for Early Cancer Detection
Date added: May, 2023

  • Study Information: NCT05334069/ NCTN #A212102
  • Sponsor: Alliance for Clinical Trials in Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Arturo Loaiza-Bonilla, MD, MDEd, FACP, Health System Director, Office of Clinical Research
  • Contact: Office of Clinical Research at 609-394-4130

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Date added: May, 2023

  • Study Information: NCT04871542/NCTN #S2013
  • Sponsor: SWOG Cancer Research Network
  • Collaborator: National Cancer Institute (NCI) 
  • Information provided by (Responsible Party): SWOG Cancer Research Network
  • Principal Investigator: Arturo Loaiza-Bonilla, MD, MDEd, FACP, Health System Director, Office of Clinical Research
  • Contact: Office of Clinical Research at 609-394-4130

Urogenital Studies

DIAGNOSTIC MARKERS IN PATIENTS WITH BLADDER CANCER

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS.
Date added: January, 2023

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)
Date added: May, 2023

  • Study Information: NCT05605964
  • Sponsor: Myovant Sciences GmbH
  • Information provided by (Responsible Party): Myovant Sciences GmbH
  • Principal Investigator: Eric Mayer, MD, Director, Urologic Robotic Surgery, Director, Center for Retroperitoneal Malignancies
  • Contact: Office of Clinical Research at 609-394-4130

Breast Studies

ASCENT-03-GS-US-592-6238A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Date added: January, 2023

S1706 A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.
Date added: January, 2023

NRG-BR007 DEBRA :A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage, Hormone Sensitive, HER2-Negative, Oncotype recurrence Score ≤ 18 Breast Cancer.
Date added: January, 2023

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Date added: May, 2023

  • Study Information: NCT05568472/NCTN #S2010
  • Sponsor: SWOG Cancer Research Network
  • Collaborator: National Cancer Institute (NCI) 
  • Information provided by (Responsible Party): SWOG Cancer Research Network
  • Principal Investigator: Arturo Loaiza-Bonilla, MD, MDEd, FACP, Health System Director, Office of Clinical Research
  • Contact: Office of Clinical Research at 609-394-4130

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer EMBER-4
Date added: May, 2023

  • Study Information: NCT05514054
  • Sponsor: Eli Lilly and Company
  • Information provided by (Responsible Party): Eli Lilly and Company
  • Principal Investigator: Erica Linden, MD, Medical Director of Breast Oncology and Cancer Genetics
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

For Medical Professionals & Employees

609-537-6363

One Capital Way
Pennington, NJ 08534

Icon-twitter-1 Icon-youtube-1 Instagram Linkedin
Careers

For Patients & Visitors

Resources

Visit Main Site
609-537-6363

One Capital Way
Pennington, NJ 08534

Icon-twitter-1 Icon-youtube-1 Instagram Linkedin
Careers

For Medical Professionals & Employees

For Patients & Visitors

Resources

Visit Main Site

© 2022 Capital Health. All rights reserved. Capital Health is a 501(c)(3) organization.

Accessibility by WAH
MAKE AN APPOINTMENT